Contrasting SurModics (SRDX) and Sientra (SIEN)

SurModics (NASDAQ: SRDX) and Sientra (NASDAQ:SIEN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, profitability, risk and earnings.

Valuation & Earnings

This table compares SurModics and Sientra’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SurModics $73.11 million 4.94 $3.92 million $0.29 95.00
Sientra $20.73 million 12.62 -$40.16 million ($2.85) -4.73

SurModics has higher revenue and earnings than Sientra. Sientra is trading at a lower price-to-earnings ratio than SurModics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for SurModics and Sientra, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SurModics 0 0 2 0 3.00
Sientra 0 1 4 0 2.80

SurModics presently has a consensus target price of $40.00, suggesting a potential upside of 45.19%. Sientra has a consensus target price of $15.00, suggesting a potential upside of 11.19%. Given SurModics’ stronger consensus rating and higher possible upside, research analysts clearly believe SurModics is more favorable than Sientra.

Insider and Institutional Ownership

85.6% of SurModics shares are held by institutional investors. Comparatively, 76.6% of Sientra shares are held by institutional investors. 6.4% of SurModics shares are held by company insiders. Comparatively, 28.1% of Sientra shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

SurModics has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Sientra has a beta of -1.47, meaning that its stock price is 247% less volatile than the S&P 500.


This table compares SurModics and Sientra’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SurModics 5.37% 6.18% 5.11%
Sientra -169.77% -68.82% -43.13%


SurModics beats Sientra on 10 of the 13 factors compared between the two stocks.

SurModics Company Profile

Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company’s In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.

Sientra Company Profile

Sientra, Inc. is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons. Its breast implants are primarily used in elective procedures, which are generally performed on a cash-pay basis. TRUE Texture provides texturing on the implant shell that is designed to reduce the incidence of malposition, rotation and capsular contracture. The Company also offers breast tissue expanders and a range of other aesthetic and specialty products. The Company offers a range of HSC+ breast implants, including anatomically shaped textured, round textured and round smooth. The Company also offers miraDry system, the device to reduce underarm sweat, odor and permanently reduce hair of all colors.

What are top analysts saying about SurModics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for SurModics and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit